The results from MGH and University of Houston were both in concordance with blood culture, providing species-specific results in roughly two hours.

T2 Biosystems CEO John McDonough said these new data further demonstrate that the T2MR platform can speed up identification of candidemia in patients with Candida infections and will result in clinical benefits.

"We expect to initiate a large-scale clinical trial of the T2Candida assay and the T2Dx instrument in 2012, and we are actively expanding our T2 molecular and immunoassay pipelines while pursuing optimal partnerships to apply our technology to additional areas of medical need," McDonough said.